TY - JOUR
T1 - A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease
AU - Falloon, Katherine
AU - Cohen, Benjamin
AU - Ananthakrishnan, Ashwin N.
AU - Barnes, Edward L
AU - Bhattacharya, Abhik
AU - Colombel, Jean Frederic
AU - Cross, Raymond K
AU - Driscoll, Marcia S.
AU - Fernandez, Anthony P.
AU - Ha, Christina
AU - Herfarth, Hans
AU - Horst, Sara
AU - Hou, Jason
AU - Husni, M. Elaine
AU - Kroshinsky, Daniela
AU - Kuhn, Kristine A.
AU - Lowder, Careen Y.
AU - Martin, George
AU - Parikh, Deep
AU - Sayed, Christopher J.
AU - Schocket, Lisa
AU - Siaton, Bernadette C.
AU - Vedak, Priyanka
AU - Weisman, Michael H.
AU - Rieder, Florian
N1 - Funding Information:
: AA has served on the scientific advisory boards of Gilead, Ikena therapeutics, and Sun Pharma. Ananthakrishnan is supported by grants from the National Institutes of Health, Crohn’s and Colitis Foundation, and Chleck Family Foundation. APF is an investigator for Pfizer, Corbus, Mallinckrodt, and Novartis and receives personal research support from Mallinckrodt and Novartis; honorarium from AbbVie, BMS, Novartis, Alexion, UCB, Boeringer‐Ingelheim, and Mallinckrodt for consulting and advisory board participation, and honorarium from AbbVie, Novartis, Kyowa Kirin, and Mallinckrodt for teaching and speaking. ELB is a consultant for AbbVie, Gilead, Pfizer, and Target RWE. BLC receives the following financial support: Advisory Boards and Consultant for Abbvie, Celgene‐Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Takeda, TARGET RWE; CME Companies: Cornerstones, Vindico; Speaking: Abbvie; Educational Grant: Pfizer. RKC receives income from consulting and participation in advisory boards from Abbvie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Samsung Bioepis, and Takeda. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc., Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix; and hold stock options in Intestinal Biotech Development. KF is supported by a grant from the Crohn's and Colitis Foundation. CH is on the advisory board for Abbvie, Janssen, Genentech, InDex Pharmaceuticals, Takeda, Pfizer, and Bristol Myers Squibb. She has research collaborations (nonfunded) with Abbvie, Genentech, Lilly, and Pfizer. She receives grant support from Pfizer. She is on the speakers’ bureau for Abbvie. HH receives research support from Allakos, Artizan, NovoNordisk, Pfizer, and consulting fees from Alivio, BMS, Boehringer, ExeGi Pharma, Finch, Gilead, Janssen, Pfizer, Pure Tech, and Otsuka. SH has served as a consultant for Abbvie, Janssen, UCB, Takeda, and Gilead. JH has received research funding from Redhill Biosciences, Janssen, Abbvie, Celgene, Genentech, Eli‐Lily, Lycera, and Pfizer Inc. JH is supported in part by resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13‐413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. GRM serves on Scientific Advisory Boards for Almirall, Incyte, Pfizer, Lilly, UCB, Dermavent, Trevi, Abbvie, Bristol Meyers Squibb (BMS), Celgene, and LEO; is a consultant for Pfizer, Almirall, Abbvie, Lilly, Biofrontera, UCB, Galderma, Scientist, Dermavent, Bausch/Ortho, Incyte, BMS, Celgene, and LEO; is a speaker for Incyte, UCB, LEO; and owns stock in Doc Martins of Maui Sunscreen Company. FR is on the advisory board for or consultant to Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer Ingelheim, Celgene/BMS, CDISC, Cowen, Ferring, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, fPliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, and 89Bio. FR is supported by grants from the National Institutes of Health (K08DK110415 and R01DK123233), Crohn’s and Colitis Foundation, Rainin Foundation, and the Helmsley Charitable Trust through the Stenosis Therapy and Anti‐Fibrotic Research (STAR) Consortium. CS has received honoraria as a speaker from Abbvie and Novartis, honoraria for consulting from Abbvie, Novartis, and UCB. Investigator fees are paid to the institution by Abbvie, Novartis, UCB, InflaRx, Incyte, and Chemocentryx. Consulting fees are paid to the institution by UCB. Declaration of personal interests
Funding Information:
We would like to acknowledge our four patient representatives for their substantial and meaningful contributions to this manuscript: Tina Aswani-Omprakash, MPH Candidate 2023. Mount Sinai School of Medicine, Founder of Own Your Crohn’s, Co-Founder of South Asian IBD Alliance and IBDesis Jessica Caron, MS, Founder of Chronically-Jess.com Gaylyn Henderson, Founder of Gutless and Glamorous, Inc. Alison Rothbaum, Founder of Empowering Patients, LLC. Their insights are greatly appreciated.
Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022/5
Y1 - 2022/5
N2 - Background and aims: Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. Methods: As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. Results: For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. Conclusions: Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.
AB - Background and aims: Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. Methods: As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. Results: For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. Conclusions: Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.
UR - http://www.scopus.com/inward/record.url?scp=85125997449&partnerID=8YFLogxK
U2 - 10.1111/apt.16853
DO - 10.1111/apt.16853
M3 - Article
C2 - 35277863
AN - SCOPUS:85125997449
VL - 55
SP - 1179
EP - 1191
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 9
ER -